clinical trial · NCT05543928
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
Chronic Kidney Disease stage3Chronic Kidney Disease stage4Vitamin d DeficiencySecondary HyperparathyroidismCTAP101Placebo
brief summary
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.
started
Jan 31, 2023
primary completion
Jun 19, 2024
completion
Jun 19, 2024
last updated
Jul 25, 2025
official title
A Multi-Center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CTAP101 Extended-release Capsules to Treat Secondary Hyperparathyroidism in Pediatric Subjects of Ages 8 to <18 Years With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol